Green, Volat Transition from the MAPS Board of Directors to Committee Members
January 14, 2026
January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors. Mr. Green joined the MAPS board in December 2020 and — among other …
MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilot
December 23, 2025
December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense …
Rescheduling Cannabis Doesn’t End Prohibition’s Harms…
December 18, 2025
The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment …
Ohio State’s Center for Psychedelic Drug Research and Education collaborates with MAPS for the Ohio P.E.A.C.E. program
November 17, 2025
Using funding provided by the Ohio Department of Behavioral Health, the Center for Psychedelic Drug Research and Education (CPDRE) will equip more than 127,000 Ohio professionals with skills in psychedelic …
MAPS and HoloMind Institute Host International MDMA-Assisted Therapy Training in Poland
October 8, 2025
San Jose, CA | October 6, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is partnering …
MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors
September 9, 2025
September 9, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, today announced that its …
MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy
September 4, 2025
San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy …
MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans
August 27, 2025
August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization …
MAPS Urges Action: Open Letter to HHS Secretary and FDA Commissioner One Year After FDA Denial of MDMA-Assisted Therapy for PTSD
August 14, 2025
WASHINGTON, DC (August 14, 2025) — One year after the FDA’s denial of the New Drug Application for MDMA-assisted therapy for PTSD, the Multidisciplinary Association for Psychedelic Studies (MAPS) has …
Statement: Confirmation of DEA Administrator Terrance C. Cole
July 23, 2025
On Tuesday, the Senate officially confirmed Terrance Cole as the new Administrator of the Drug Enforcement Administration (DEA), marking the first permanent leadership appointment to the agency under President …
Following Psychedelic Science 2025 Success, MAPS Publishes First of Hundreds of Conference Session Videos
July 16, 2025
July 16, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of its enhanced Virtual Trip video conference platform featuring the first selection of videos from …
Plant Medicine Track at Psychedelic Science 2025 Spotlights Ancestral Wisdom, Indigenous Sovereignty, and Being in Right Relationship
June 12, 2025
DENVER, June 12, 2025 (GLOBE NEWSWIRE) — With growing recognition of psychedelics and plant medicines in therapeutic and scientific settings, it is a critical time to uplift and acknowledge the Indigenous …